How the FDA could rapidly generate jobs and increase safety
By Steven Greer, MD Updated August 17, 2012 September 4, 2010, The economy is in a double-dip recession with jobs growth decreasing each month. Retail companies like Amazon.com and Apple are missing...
View ArticleThe most important stories in healthcare 2012
December 24, 2012 By Steven E. Greer, MD 2012 was quite similar to 2011 and the previous five years. Times were tough as the global economic depression upended the traditional business models of...
View ArticleWhich mobile apps will the FDA regulate and tax?
March 23, 2013 The House Energy and Commerce Committee convened a three-day oversight hearing to learn more details from the FDA on which mobile apps dealing with healthcare will be deemed worthy of...
View ArticleNew FDA paradigms for cancer drug approval and trial design
(In 1080iHD full screen) In the last part of our interview with Dr. Janet Woodcock, Director of the FDA’s new drug division CDER, Steven Greer, MD asks how progressed the agency is with incorporating...
View ArticleThe FDA’s new Breakthrough designation for new drug approvals
Courtesy of The Healthcare Channel, Dr. Janet Woodcock, the Director of the FDA’s drug division, CDER, discusses the newly created “Breakthrough” pathway for new drug applications. Distinct from...
View ArticleFDA CDER Director on Benlysta for lupus and adaptive clinical trials.
(In 108iHD) Janet Woodcock, MD, Director of the FDAs new drug division, CDER, discusses with Steven Greer, MD the first drug approved to treat lupus in 50 years, Benlysta (belimumab). The BLISS trials...
View ArticleFDA official, William Maisel, pleads guilty to crime, keeps job
April 24, 2013 By Steven E. Greer, MD In July of 2012, the New York Times reported on an FDA scandal of the agency spying on internal whistleblowers, by hacking into their work and personal emails. The...
View ArticleThe IOM report on counterfeit and substandard drugs
Prashant Yadav, PhD, Director, Health Care Research Initiative, University of Michigan, discusses the IOM report he helped author that investigated the extent of the problem of counterfeit and...
View ArticleFDA’s CDER Director: The problem of outsourced clinical trials
Janet Woodcock, MD, the Director of the FDA’s CDER, the division that approved pharmaceuticals, discusses the problem of more and more clinical trials being conducted in small countries around the...
View ArticleSandra Kweder, MD: The FDA’s plan of action to alleviate cancer drug shortages
November 10, 2011 By Steven Greer, MD Sandra Kweder, MD Deputy Director of the Office of New Drugs at the FDA discusses the plan of action already underway, and ordered by President Obama, to alleviate...
View Article
